Transce3nd’s Quest Diagnostics DGX Stock Holding History

Transce3nd’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$539	–	391
2025 Q2	$539	Hold	3	–	–	﹤0.01%	1072
2025 Q1	$508	Sell	3 -46	-94%	-$7.56K	﹤0.01%	1034
2024 Q4	$7.39K	Buy	+49	New	+$7.62K	﹤0.01%	827

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Transce3nd's DGX Position: Q3 2025 in Review

Transce3nd sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 3 shares — an estimated $539 sold.

Transce3nd first reported a position in DGX in Q4 2024 and held it in 3 quarters. The position peaked at $7.39K in Q4 2024. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

Transce3nd reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 3 Quest Diagnostics shares in Q3 2025, an estimated $539.
Transce3nd first reported a position in Quest Diagnostics in Q4 2024 and held it in 3 quarters.
Transce3nd's Quest Diagnostics position peaked at $7.39K in Q4 2024.
1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.